A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 08 Mar 2018 Planned number of patients changed from 30 to 35.
- 06 Mar 2017 Planned End Date changed from 1 Mar 2021 to 1 Mar 2019.
- 06 Mar 2017 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2019.